Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Financing Activities: 2016-2025

Historic Cash from Financing Activities for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $1.1 million.

  • Akebia Therapeutics' Cash from Financing Activities fell 8.99% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.1 million, marking a year-over-year increase of 284.29%. This contributed to the annual value of $49.7 million for FY2024, which is 297.03% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Cash from Financing Activities of $1.1 million as of Q3 2025, which was down 35.29% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Cash from Financing Activities ranged from a high of $74.9 million in Q1 2025 and a low of -$32.9 million during Q3 2022.
  • Its 3-year average for Cash from Financing Activities is $9.3 million, with a median of $1.2 million in 2024.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 128,900.00% in 2023, then spiked by 2,346.00% in 2024.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Cash from Financing Activities stood at $5.4 million in 2021, then tumbled by 100.02% to -$1,000 in 2022, then tumbled by 128,900.00% to -$1.3 million in 2023, then spiked by 1,830.62% to $22.3 million in 2024, then declined by 8.99% to $1.1 million in 2025.
  • Its Cash from Financing Activities stands at $1.1 million for Q3 2025, versus $1.7 million for Q2 2025 and $74.9 million for Q1 2025.